Friday - May 16, 2025
BURLINGTON, Mass. / Mar 01, 2023 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will participate in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place in Boston, MA on March 6-8, 2023. Heather Getz, Executive Vice President & Chief Financial Officer, Darius Shahida, Chief Strategy Officer & Chief Business Development Officer, and Dr. John Martin, Chief Medical Officer will participate in a fireside chat on March 7, 2023 at 2:10 pm Eastern Time.
A live webcast of the presentation will be available in the Events & Presentations section of the Butterfly Network investor website.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.
Last Trade: | US$2.30 |
Daily Change: | -0.01 -0.43 |
Daily Volume: | 2,294,939 |
Market Cap: | US$429.270M |
February 28, 2025 January 29, 2025 January 13, 2025 January 08, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load